Rimondi Alessandro

Dr. Rimondi Alessandro

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
GTGian Eugenio Tontini
Gian Eugenio Tontini
RARimondi Alessandro
Rimondi Alessandro
MVMarta Vernero
Marta Vernero
HNHelmut Neumann
Helmut Neumann
MVMaurizio Vecchi
Maurizio Vecchi
FCFlaminia Cavallaro
Flaminia Cavallaro
Since the advent of artificial intelligence (AI) in clinical studies, luminal gastrointestinal endoscopy has made great progress, especially in the detection and characterization of neoplastic and preneoplastic lesions. Several studies have recently shown the potential of AI-driven endoscopy for the investigation of inflammatory bowel disease (IBD). This systematic review provides an overview of the current position and future potential of AI in IBD endoscopy. A systematic search was carried out in PubMed and Scopus up to 2 December 2020 using the following search terms: artificial intelligence, machine learning, computer-aided, inflammatory bowel disease, ulcerative colitis (UC), Crohn’s disease (CD). All studies on human digestive endoscopy were included. A qualitative analysis and a narrative description were performed for each selected record according to the Joanna Briggs Institute methodologies and the PRISMA statement. Of 398 identified records, 18 were ultimately included. Two-thirds of these (12/18) were published in 2020 and most were cross-sectional studies (15/18). No relevant bias at the study level was reported, although the risk of publication bias across studies cannot be ruled out at this early stage. Eleven records dealt with UC, five with CD and two with both. Most of the AI systems involved convolutional neural network, random forest and deep neural network architecture. Most studies focused on capsule endoscopy readings in CD (n = 5) and on the AI-assisted assessment of mucosal activity in UC (n = 10) for automated endoscopic scoring or real-time prediction of histological disease. AI-assisted endoscopy in IBD is a rapidly evolving research field with promising technical results and additional benefits when tested in an experimental clinical scenario. External validation studies being conducted in large and prospective cohorts in real-life clinical scenarios will help confirm the added value of AI in assessing UC mucosal activity and in CD capsule reading. Artificial intelligence for inflammatory bowel disease endoscopy

5 December 2023 in Digestive and Liver Disease
Verified
Journal Article
Closed access
RARimondi Alessandro
Rimondi Alessandro
KGKlaus Gottlieb
Klaus Gottlieb
EDEdward J. Despott
Edward J. Despott
MIMarietta Iacucci
Marietta Iacucci
AMAlberto Murino
Alberto Murino
GTGian Eugenio Tontini
Gian Eugenio Tontini

10 May 2023 in Digestive Endoscopy
Verified
Journal Article
Open access
RARimondi Alessandro
Rimondi Alessandro
ASAndrea Sorge
Andrea Sorge
AMAlberto Murino
Alberto Murino
NNNicoletta Nandi
Nicoletta Nandi
LSLucia Scaramella
Lucia Scaramella
Luca ElliLuca Elli
Luca Elli
Blue rubber bleb nevus syndrome (BRBNS) is a rare challenging cause of gastrointestinal bleeding. We performed a systematic review of case reports and case series on BRBNS to gather information on the treatment options currently available. All studies reporting a case of BRBNS in humans were evaluated. Papers were ruled out if CARE criteria and explanations on patient's selection, ascertainment, causality, and reporting were not respected or identified. PROSPERO 2021 CRD 42021286982. Blue rubber bleb nevus syndrome was treated in 106 cases from 76 reports. 57.5% of the population was under 18 years old, and up to 50% of the cases reported a previous treatment. Clinical success was achieved in 98 patients (92.4%). Three main types of interventions were identified: systemic drug therapy, endoscopy, and surgery. After BRBNS recurrence or previous therapy failure, systemic drug therapy emerged as a preferred second-line treatment over endoscopy (P = 0.01), but with a higher rate of reported adverse events when compared with surgery and endoscopy (P < 0.001). Endoscopic treatment was associated with a higher number of required sessions to achieve complete eradication when compared with surgery (P < 0.001). No differences between the three main areas were found in the overall follow-up time (P = 0.19) or in the recurrence rate (P = 0.45). Endoscopy, surgery, and systemic drug therapy are feasible treatment options for BRBNS. Systemic drug therapy was the favorite second-line treatment after endoscopic failure or recurrence of BRBNS, but adverse events were more frequently reported.

8 April 2025 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
RARimondi Alessandro
Rimondi Alessandro
EDElisabetta Dell’unto
Elisabetta Dell’unto
RMRui Morais
Rui Morais
GEGianluca Esposito
Gianluca Esposito
JSJoão Santos-Antunes
João Santos-Antunes
AMAlberto Murino
Alberto Murino

13 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Luca ElliLuca Elli
Luca Elli
BMBeatrice Marinoni
Beatrice Marinoni
RSReena Sidhu
Reena Sidhu
CBChristian Bojarski
Christian Bojarski
FBFederica Branchi
Federica Branchi
RARimondi Alessandro
Rimondi Alessandro
(1) Background: Villous atrophy is an indication for small bowel capsule endoscopy (SBCE). However, SBCE findings are not described uniformly and atrophic features are sometimes not recognized; (2) Methods: The Delphi technique was employed to reach agreement among a panel of SBCE experts. The nomenclature and definitions of SBCE lesions suggesting the presence of atrophy were decided in a core group of 10 experts. Four images of each lesion were chosen from a large SBCE database and agreement on the correspondence between the picture and the definition was evaluated using the Delphi method in a broadened group of 36 experts. All images corresponded to histologically proven mucosal atrophy; (3) Results: Four types of atrophic lesions were identified: mosaicism, scalloping, folds reduction, and granular mucosa. The core group succeeded in reaching agreement on the nomenclature and the descriptions of these items. Consensus in matching the agreed definitions for the proposed set of images was met for mosaicism (88.9% in the first round), scalloping (97.2% in the first round), and folds reduction (94.4% in the first round), but granular mucosa failed to achieve consensus (75.0% in the third round); (4) Conclusions: Consensus among SBCE experts on atrophic lesions was met for the first time. Mosaicism, scalloping, and folds reduction are the most reliable signs, while the description of granular mucosa remains uncertain.

3 December 2025 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
EBElisabet Maristany Bosch
Elisabet Maristany Bosch
GKGeorgios Kalopitas
Georgios Kalopitas
RARimondi Alessandro
Rimondi Alessandro
HYHironori Yamamoto
Hironori Yamamoto
AMAlberto Murino
Alberto Murino
EDEdward J. Despott
Edward J. Despott
Background and Study Aims: Endoscopic submucosal dissection (ESD) is increasingly used for the resection of complex lesions of the gastrointestinal tract. However, its adoption in the management of colonic lesions in Western practice remains challenging, mainly due to the anatomical complexities of the colon. The saline‐immersion/irrigation technique (SITE), combined with the pocket‐creation method (PCM) may help to overcome these challenges. This study evaluates outcomes of SITE‐PCM ESD in a Western tertiary center. Methods: We analyzed consecutive colorectal ESD procedures performed at our center between 2017 and 2024. SITE‐PCM was used in all cases. Lesion characteristics, procedural outcomes, histopathological findings, adverse events, and follow‐up data were analyzed. Results: A total of 181 lesions in 177 patients were resected en bloc using SITE‐PCM ESD. Sixty lesions (33.1%) were located in the proximal colon, while 79 (43.6%) were rectal lesions. R0 and curative resection rates were 92.3% and 90.6%, respectively. The median procedure time was 120 min. Adverse events occurred in 4.4% of cases, with only three patients necessitating hospitalization and nonsurgical intervention due to delayed bleeding, and one patient requiring surgical management after a delayed perforation. Notably, 93.4% of the procedures were performed under conscious sedation. Conclusions: In our experience SITE‐PCM‐ESD appears to be a safe and effective minimally invasive approach for complex colorectal lesions. It achieves high R0 and curative resection rates with low adverse events and is feasible under conscious sedation. These findings support broader adoption of SITE‐PCM in Western practice and justify prospective multicenter validation.